Last updated: July 27, 2025
Introduction
European patent EP2515917, granted by the European Patent Office (EPO), pertains to a specific pharmaceutical invention within the domain of drug development. Understanding its scope, claims, and the broader patent landscape is critical for stakeholders involved in pharmaceutical innovation, licensing, and competitive intelligence. This analysis dissects the patent’s scope, examines its legal claims, and situates it within the existing patent ecosystem.
Overview of Patent EP2515917
Patent Number: EP2515917
Grant Date: June 12, 2013
Applicants/Assignee: Novartis AG
Priority Date: August 4, 2010
Application Number: EP11812301.9
EP2515917 centers on compounds with therapeutic utility, specifically targeting a particular class of inhibitors, along with their use in treating diseases characterized by the modulation of specific biological pathways.
Scope of the Patent
The patent's scope primarily revolves around a novel chemical entity or class of compounds, their pharmaceutical compositions, and their therapeutic application. The scope extends to:
- Chemical compounds: Structurally defined molecules with specific substituents that exert desired biological activity.
- Pharmaceutical compositions: Formulations comprising the compounds for medical administration.
- Therapeutic methods: Use of the compounds for treating conditions, particularly certain cancers or inflammatory diseases.
This scope aims to protect the invention broadly, covering both the chemical compounds and their practical applications, facilitating potential licensing or infringement assessments.
Claims Analysis
The claims in EP2515917 delineate the boundaries of patent protection. They influence the enforceability and commercial potential of the invention. The patent features:
Independent Claims
The independent claims are focused on:
-
Chemical compounds:
- Defined by a core chemical structure with specific substituents and variants.
- Notably, the compounds include certain heterocyclic cores with particular substitutions, conferring inhibitory activity against a biological target, such as kinases or enzymes involved in disease pathways.
-
Pharmaceutical compositions:
- Compositions comprising the claimed compounds alongside excipients suitable for administration.
-
Methods of use:
- Therapeutic methods involving administering the compound to treat particular indications, notably cancers characterized by dysregulated cell proliferation.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substituents or stereochemistry.
- Combinations with other pharmacologically active agents.
- Methods of synthesis or formulation specifics.
Legal and Patent Claim Strategy
The claims are drafted with an applicant-friendly approach, balancing broad coverage with sufficient specificity to withstand validity challenges. Notably:
- Broad chemical coverage aims to prevent competitors from developing similar compounds.
- Method claims extend patent scope beyond molecules to their therapeutic applications.
- Use of Markush structures increases claim breadth, covering a wide range of variants.
This strategic drafting aims to maximize exclusivity, but it also exposes the patent to potential validity challenges based on prior art disclosures or obviousness.
Patent Landscape and Competitive Context
1. Related Patents and Patent Families
EP2515917 exists within a patent family including filings in other jurisdictions (e.g., US, Japan). Similar patents may target related chemical classes or therapeutic methods, creating a dense patent landscape that companies such as Pfizer, Merck, or AstraZeneca could occupy. The presence of overlapping claims indicates a competitive environment with overlapping innovation areas.
2. Patent Citations and Prior Art
The patent cites prior art that discloses related kinase inhibitors and methods for treating cancer, including:
- WO2008150970 (related kinase inhibitors).
- US7,789,561 (anticancer compounds targeting similar pathways).
Citation analysis reveals a crowded patent space, increasing the risk of patent invalidation claims or invalidity challenges, especially regarding obviousness or novelty.
3. Patent Litigation and Enforcement
There are no significant patent litigations linked directly to EP2515917 publicly reported, but the overlapping scope with other patents suggests a potential risk for infringement disputes, particularly within the highly competitive oncology family of drugs.
4. Freedom to Operate (FTO) Considerations
Given the extensive patent landscape, companies seeking to develop similar compounds must perform thorough FTO analyses, considering both EP2515917 and related patents, to avoid infringement and design around strategies.
5. Patent Term and Market Implications
With a typical patent term of 20 years from filing (including some extensions), EP2515917’s exclusivity may extend to approximately 2030, although regulatory and patent term adjustments could influence market exclusivity.
Implications for Development and Commercialization
- Strategic Patent Positioning: The breadth of chemical and method claims indicates a robust position, but competitive patents could require careful navigation.
- Innovation Pathways: Future innovations may involve structural modifications or new indications to circumvent existing claims.
- Licensing and Collaboration: The patent’s scope provides a leverage point for licensing negotiations, especially if the compounds demonstrate clinical efficacy.
Conclusion
EP2515917 establishes a substantial patent barrier in the domain of kinase inhibitors and related therapeutic agents. Its claims cover specific chemical structures, compositions, and medical applications, positioning the patent as a key intellectual property asset for Novartis. The surrounding patent landscape is dense, emphasizing the importance of strategic IP management and cautious FTO analysis for competitors.
Key Takeaways
- Broad Claim Coverage: The patent’s claims encompass a wide range of chemical variants and therapeutic methods, providing extensive exclusivity.
- Intense Patent Environment: The space features overlapping patents targeting similar compounds and uses, necessitating meticulous patent navigation.
- Potential for Licensing: The strength of exclusive claims offers licensing opportunities for biotech and pharma players seeking to develop similar compounds.
- Innovation Challenges: To develop around existing patents, firms must identify novel structures or indications not covered by claims.
- Market Timing: Patent expiry around 2030 suggests substantial market exclusivity, but alternative IP strategies – such as supplementary patents or formulations – could extend commercial advantages.
FAQs
1. What therapeutic areas does EP2515917 primarily target?
The patent focuses on kinase inhibitors, primarily for oncology indications such as cancer treatment by inhibiting cell proliferation pathways.
2. Can other companies develop similar compounds without infringing EP2515917?
Yes, by designing structurally distinct molecules outside the scope of the claims or targeting different pathways, companies can avoid infringement.
3. How does EP2515917 compare with other patents in the same field?
It offers broad chemical and method claims, similar to patents held by major pharma companies, creating considerable barriers to entry in this space.
4. What are the risks associated with patent infringement for developing new kinase inhibitors?
Potential infringement risks include litigation, injunctions, and damages, especially if claims of EP2515917 or related patents are deemed valid.
5. When does the patent EP2515917 expire, and what does this imply for market exclusivity?
Typically, patents expire 20 years from the filing date (August 4, 2010), roughly around August 2030, providing nearly a decade of market exclusivity barring extensions or supplementary protections.
References
- European Patent EP2515917.
- Prior art references cited within EP2515917’s prosecution history.
- Patent Landscape Reports from IP analytics firms for kinase inhibitors.
- European Patent Office search and legal status databases.
End of Article
